# Benzofused lactams and pharmaceutical compositions containing them.

## Abstract
Benzofused lactams and salts thereof are disclosed. They are used as active ingredient of pharmaceutical compositions which are useful as cholecystokinin antagonists.

## Claims
Patent claims 1. A compound of formula I or IIEMI54.1 wherein in formulae I and IIR is lower C1 C8 alkyl C6 or C10 aryllower C1 C8 alkyl lower C1 C4 alkyl containing a carbonyl group which carbonyl group can be substituted with C1 C4 alkyl, hydroxy, C1 C4alkoxy, or NR wherein R is hydrogen, C1 C4alkyl, carboxyloweralkyl, carboxamidoloweralkyl, arylalkyl wherein the aryl is C5 C10 and the alkyl is C1 C4 R6 is hydrogen halo kydroxy C 1 C8alkyl lower C1 C8 alkoxy and y is 1 3 and wherein in formula II the radical R1 and in formula I the radicalsR1 and R2 have independently the following meaning hydrogen lower C1 C8alkyl unsubstituted or substituted carbonyl wherein the substituents are alkoxy, alkyl of C1 C8, hydroxyalkyl of C1 C8, amino, loweralkylamino, C6 or C10 arylloweralkylamino, carboxylower alkylamino, carboxamidoloweralkylamino groups of formula NR4R5 wherein and R5 can indpendently be unsubstituted or substituted carbonyl, or unsubstituted or substituted carboxyloweralkyl, or unsubstituted or substituted carboxamido loweralkyl wherein the substituents are C1 C4alkyl, C1 C4alkyloxy C6 or C10 arylloweralkyl, C6 C10 aryllower alkoxy, arninoloweralkyl, substituted aminoloweralkyl substituted loweralkyl wherein the substituents are halo, hydroxy, carboxy, carboxamido, carbonyl, substituted carbonyl wherein the substituent is C1 C8 alkyl OII, loweralkylthio, lowera lkoxy, loweralkoxy carbonyl, lower C6 or C10 arylalkoxycarbonyl, amino, loweralkylamino, lowerdialkylamino, acylamino substituted loweralkylamino wherein the substituent can be halo, hydroxy, alkoxy or cyano C6 or C10 arylloweralkylamino C6 or C10 aryloxy C6 or C10 arylthio C6 or C10 arylalkyloxy C6 or C10 arylalkylthio benzofused cycloalkyl or bicycloalkyl of from 8 12 carbon atoms aryl or heteroaryl wherein the aryl is C6 or C10 and the heteroaryl contains an 0, N or S heteroatom and which aryl group or heteroaryl group may be mono, di or trisubstituted by loweralkyl, hydroxy, loweralkoxy, halo, amino, acylamino, loweralkylthio or aminoloweralkyl benzofused cycloalkyl or bicycloalkyi of from 8 to 12 carbon atoms C6 or C10 arylloweralkyl C6 or C10 arylloweralkenyl heteroarylloweralkyl and heteroarylloweralkenyl in which the aryl rings may be mono , di or trisubstituted by halo, loweralkyl, hydroxy, loweralkoxy, amino, loweralkylamino, diloweralkylamino, aminoloweralkyl, acylamino, carboxy, haloloweralkyl, nitro, cyano or sufonamido aryla lkyl or heteroarylalkyl wherein the aryl is C6 Ol C10 and the heteroaryl contains an 0, N or S heteroatom and which include branched loweralkyl groups substituted arylalkyl or substituted heteroarylalkyl which include branched loweralkyl groups wherein the loweralkyl groups can be substituted by amino, acylamino, or hydroxy and the aryl groups are C6 or C10 and the heteroaryl contain O, N or S heteroatoms and wherein the aryl group .ncl the heteroaryl group is optionally substituted by halo, dihalo, loweralkyl, hydroxy, loweralkoxy,C6 or C10 aryloxy, C6 or C10 aroyl, C6 or C10 arylthio, amino, aminoloweralkyl, loweralkanoyl amino, C6 or C10 arylamino, lowerdialkylamino, loweralkylamino, hydroxy, hydroxyloweralkyl, trihaloloweralkyl, nitro, cyano, or sulfonamido and any of the arylalkyl groups, arylalkenyl groups, heteroarylalkyl groups or heteroarylalkenyl groups described above in which the aryl ring or heteroarylring is partially or completely hydrogenated substituted loweralkyl having the FormulaRA1 CH2 n Q CH2 m wherein n is 0 2, in is 1 3, is aryl or heteroaryl wherein the aryl is C6 orC10 and the heteroaryl contains an O, N or S heteroatom and the aryl group or heteroaryl group is optionally substituted by amino, lowerdialkylamino, loweralkylamino, hydroxy, hydroxyloweralkyl, aminoloweralkyl, trihaloloweralkyl, cyano, nitro, sulfonamido, C6 C10 aroyl, loweralkyl, halo, dihalo, and loweralkoxy and is a bivalent group having the formulae O, S, SO, SO2, N RB1, CONRC1, NRC1CO or CH CH wherein is is hydrogen, loweralkyl, C6 or C10D aryl, C6 or C01 arylalkyl, lower alkanoyl, or C6 or C10 aroyl, and is is hydrogen, or loweralkyl and wherein in formula I p is 1 or 2 and X is absent or carbonyl and salts of the compounds of formulae.I and II. 2. A compound o claim 1 wherein in formulae I and II R1 is an optionally substituted aryl group having 6 or 10 carbon atoms, an optionally substituted heteroaryl group in tich the heteroatom is oxygen, sulfur and preferably nitrogen or an alkyl group substituted with an optionally substituted aryl or an optionally substituted heteroaryl group in which the heteroatoms are oxygen, sulfur and preferably nitrogen, or a salt of the compounds of formulae I and II. 3. A compound of claim 1 or 2 having the formula I wherein p is 1, or a salt of said compounds. 4. A compound of one of the claims 1 3 which is a member of the group comprisillg 1 methyl 3 1 carboethoxy 3 phenyl 1 propyl amino homodihydrocarbostyril 1 carbomethoxymethyl 3 3 indole methyl amino homodihydrocarbostyril 1 carbomethoxymethyl 3 1 2 hydroxy 1 oxoethyl 3 phenyl 1 propyl aminohomodihydrocarbostyriyl 1 t butoxycarbonylmethyl 3 L D N acetyltryptophanyl aminohomodihydrocarbostyril l t butoxycarbonylmethyl 3 L N acetyltryptophanyl aminohomodihydrocarbostyril 1 t butoxycarbonylmethyl 3 L carbobenzyloxy tryptophanyl aminohomodihydrocarbostyril l t butoxycarbonylmethyl 3 D N carbobenzyloxy tryptophanyl aminohomodihydrocarbostyril l carbo 5 butoxymethyl 3 carbonyl 2 indolyl amino homodihydrocarbostyril l carboxymethyl 3 carbonyl 2 indolyl amino homodihydrocarbostyril l carbo t butoxymethyl 3 3, 4 dichlorobenzoyl amino homodihydrocarbostyril, and salts of said compounds. 5. A pharmaceutical composition for treating gastrointestinal disorders, central nervous system disorders, or regulating appetite in mammals, preferably human beings, characterized in that it contains as pharmaceutically effective ingredient a compound of formulae I or II according to patent claim 1 or a pharmaceutically acceptable salt of the compounds of formulae I or II. 6. A pharmaceutical composition accord.ing to claim 5 characterized in that it contains as active ingredient a compound of formulae I or II according to patent claim 2 or a pharmaceutically acceptable salt of said compounds. 7. A pharmaceutical composition according to patent claim 5 or 6 characterized in that it contains a compound of formula I according to patent claim 3 or a pharmaceutically acceptable salt thereof. 8. A pharmaceutical composition according to one of the patent claims 5 7 characterized in that it contains as active ingredient a compound of claim 4 or a pharmaceutically aceeptable salt thereof. 9. A pharmaceutical composition according to one of the patent claims 5 8 characterized in that it contains as further ingredient a pharmaceutically acceptable carrier.

## Description
TITLE OF THE INVENTIONBenzofused lactams and pharmaceutical compositions containing them.BACKGROUND OF THE INVENTION Cholecystokinin CCK is a neuropeptide composed of thirty three aminoacids. See Mutt andJorpes, Biochem. J. 125 678 1971 . The carboxyl terminal octapeptide CCK 8 also occurs naturally and is fully active. CCK exists in both gastrointestinal tissue and the central nervous system. IV. Mutt, Gastrointestinal Hormones, G. B. J. Glass, Ed., Raven Press, N.Y., 1980 p. 169. CCK is believed to play an important role in appetite regulation and CCK may be a physiological satiety hormone. G. P. Smith, Eating and Its Disorders, A.J. Stunkard and E. Stellar, Eds, Raven Press, NewYork, 1984, p. 67. Among additional effects of CCX are stimulation of colonic motility, stimulation of gall bladder contraction, stimulation of pancreatic enzyme secretion, and inhibition of gastric emptying. CCX reportedly co exists with dopamine in certain mid brain neurons and thus may also play a role in the functioning of dopaminergic systems in the brain as well as serving as a neurotransmitter in its own right. See A. J. Prange et al., Peptides in theCentral Nervous System , Ann. Repts. Med. Chem. 17 31, 33 1982 and references cited therein J. A.Williams, Biomed. Res. 3, 479 107 1982 and J. E.Morley, Life Sci. 30 1982 1. CCX antagonists are useful in the treatment and prevention of CCK related disorders of the gastrointestinal, central nervous and appetite regulatory systems of animals, especially humans.Three distinct chemical classes of CCK receptor antagonists have been reported. One class comprises derivatives of cyclic nucleotides detailed structure function studies have demonstrated that of the various members of this class, dibutyryl cyclicGMP is the most potent. See N. Barlos et al., Am.J. Physiol., 242, G161 1982 and P. Robberecht et al., Mol., Pharmacol., 17, 268 1980 . The second class comprises peptide antagonists which areC terminal fragments and analogs of CCK. Recent structure function studies have shown that both shorter C terminal fragments of CCX Boc Met Asp Phe NH2, Met Asp Phe NH2 as well as longer CCX fragments Cbz Tyr S03H Met Gly TrpMet Asp NH2 can function as CCX antagonists. See R. T. Jensen et al., Biochim. Biophys. Acta., 757, 250 1983 and M. Spanarkel et al., J. Biol. Chem., 258, 6746 1983 . The third class of CCK receptor antagonists comprises the amino acid derivatives proglumide, a derivative of glutaramic acid, and theN acyl tryptophans including para chlorobenzoyl Ltryptophan benzotript . See W. F. Hahne et al.,Proc. Natl. Acad. Sci.U.S.A., 78, 6304 1981 andR. T. Jensen et al., Biochem. Biophys. Acta., 761, 269 1983 . All of these compounds are relatively weak antagonists of CCX IC50 10 4 10 6M . SUMMARY OF THE INVENTION It has now been found that compounds of this invention are antagonists of cholecystokinin CCX . These CCX antagonists are useful in the treatment and prevention of CCK related disorders of the gastrointestinal, central nervous and appetite regulatory systems of mammals, especially humans.DETAILED DESCRIPTION OF THE INVENTION The compounds of this invention are benzofused lactams of the formula EMI3.1 wherein X is absent or carbonyl R is lower C1 C8alkyl C6 or C10 aryllower Cl C8alkyl lower Cl C4alkyl containing a carbonyl group which carbonyl group can be substituted with C C4alkyl, hydroxy, C C alkoxy, or NR wherein R3 .is hydrogen, C1 C4alkyl, carboxyloweralkyl, carboxamidoloweralkyl, arylalkyl wherein the aryl is C5 C10 and the alkyl is 2C1 C4 R1 and R are independently hydrogen lower C1 C8alkyl unsubstituted or substituted carbonyl wherein the substituents are alkoxy, alkyl of C1 C8, hydroxyalkyl of C1 C8, amino, loweralkylamino, C6 or C10 arylloweralkylamino, carboxylower alkylamino, carboxamidoloweralkylamino NR4R5 wherein R4 and R5 can independently be unsubstituted or substituted carbonyl, or unsubstituted or substituted carboxyloweralkyl, or unsubstituted or substituted carboxamidoloweralkyl wherein the substituents are C1 C4alkyl, C1 C4alkyloxy, C6 or C10 aryl loweralkyl, C6 C10 arylloweralkoxy, aminoloweralkyl, substituted aminoloweralkyl substituted loweralkyl wherein the substituents are halo, hydroxy, carboxy, carboxamido, carbonyl, substituted carbonyl wherein the substituent is C1 C8 alkyl OH, loweralkylthio, loweralkoxy, loweralkoxycarbonyl, lower C6 or C10 arylalkoxycarbonyl, amino, loweralkylamino, lowerdialkylamino, acylamino substituted loweralkylamino wherein the substituent can be halo, hydroxy, alkoxy or cyano C6 or C10 arylloweralkylamino C6 or C10 aryloxy C6 or C10 arylthio C6 or C10 arylalkyloxy C6 or C10 arylalkylthio benzofused cycloalkyl or bicycloalkyl of from 8 12 carbon atoms aryl or heteroaryl wherein the aryl is C6 or C10 containing an O, N or S heteroatom and which may be mono , di or trisubstituted by loweralkyl, hydroxy, loweralkoxy, halo, amino, acylamino, loweralkylthio or aminoloweralkyl benzofused cycloalkyl or bicycloalkyl of from 8 to 12 carbon atoms C6 or C10 arylloweralkyl C6 or C10 arylloweralkenyl heteroloweralkyl and heteroloweralkenyl in which the aryl or heteroaryl rings may be mono , di or tri substituted by halo, loweralkyl, hydroxy, loweralkoxy, amino, loweralkylamino, diloweralkylamino, aminoloweralkyl, acylamino, carboxy, haloloweralkyl, nitro, cyano or sulfonamido arylalkyl or heteroarylalkyl wherein the aryl is C6 or C10 containing an O, N orS heteroatom and which include branched loweralkyl groups substituted arylalkyl or substituted heteroarylalkyl which include branched loweralkyl groups wherein the loweralkyl groups can be substituted by amino, acylamino, or hydroxyl and the aryl and heteroaryl groups are C6 or C10 containing an O, N or S heteroatom and can be substituted by halo, dihalo, loweralkyl, hydroxy, loweralkoxy, C6 or C10 aryloxy,C6 or C10 aroyl, C6 or C10 arylthio, amino, aminoloweralkyl, loweralkanoylamino,C6 or C10 aroylamino, lowerdialkylamino, loweralkylamino, hydroxy, hydroxyloweralkyl, trihaloloweralkyl, nitro, cyano, or sulfonamido any of the arylloweralkyl or alkenyl and heteroloweralkyl or alkenyl groups described above in which the aryl or heteroaryl ring is partially or completely hydrogenated substituted loweralkyl having the formula RA CH2 n Q CH2 m wherein n is 0 2, m is 1 3, A is aryl or heteroaryl wherein the aryl is C6 or C10 containing an O, N or S heteroatom optionally substituted by amino, lowerdialkylamino, loweralkylamino, hydroxy, hydroxyloweralkyl, aminoloweralkyl, trihaloloweralkyl, cyano, nitro, sulfonamido, C6 C10 aroyl, loweralkyl, halo, dihalo, and loweralkoxy, and Q is O, S, SO, SO2, N RB ,CONRC1, NRC1CO, CH CH wherein 1 is hydrogen, loweralkyl, C6 or RB C10 aryl, C6 or C10 arylalkyl, loweralkanoyl, or C6 or C10 aroyl, and R1 C hydrogen, or loweralkyl Rod is hydrogen halo hydroxy C1 C8alkyl lowerC1 C8alkoxy y is 1 3 p is 0 2 with the proviso that when p is O, X is carbonyl and, the pharmaceutically acceptable salts thereof. The straight chain, branched, saturated and unsaturated hydrocarbons recited above are represented by such compounds as methyl, ethyl, n propyl, i propyl, n butyl, i butyl, t butyl, n pentyl, i pentyl, n hexyl or vinyl, allyl, butenyl, and the like. The loweralkoxy substituent represents a loweralkyl group attached through an oxygen bridge. The arylalkyl and heteroarylalkyl substituents recited above represent aryl or heteroaryl groups as herein defined attached through a straight or branched chain hydrocarbon of from one to eight carbon atoms such as, for example, benzyl, phenethyl, 3,3 diphenylpropyl, 3 indolylmethyl, and the like. Halo means chloro, bromo, iodo, or fluoro. The aryl substituent is illustrated by phenyl, naphthyl, or biphenyl. The heteroaryl substituent recited above represents any 5 or 6 membered aromatic ring containing from one to three 0, N or S heteroatoms such as, for example, pyridyl, thienyl, furyl, imidazolyl, and thiazolyl as well as any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring such as, for example, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, and benzthienyl. The acylamino substituent represents loweralkanoylamino, arylalkoxycarbonyl, alkyloxycarbonyl, and aroylamino, such as acetylamino, benzyloxycarbonylamino, and benzoylamino. The Formula 1 compounds can be used in the form of salts derived from inorganic or organic acids and bases. Included among such acid addition salts are the following acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2 hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2 naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3 phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate.Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine and N methyl D glucamine, and salts with amino acids such as arginine, lysine, and so forth. Water or oil soluble or dispersible products are thereby obtained. An embodiment of this invention is the use of the compounds of Formula 1 for the treatment and the prevention of disorders of the gastrointestinal, central nervous, and appetite regulatory systems of mammals, especially of man. Specifically, theFormula 1 compounds are useful in treatment and prevention of disorder of gastric acid secretion, gastrointestinal motility, pancreatic secretions, and dopaminergic functions. The compounds of Formula 1 are especially useful in the prevention and treatment of irritable bowel syndrome. The ability of the compounds of Formula 1 to antagonize CCX makes these compounds especially useful in the treatment and prevention of disease states wherein CCX may be involved, for example, gastrointestinal disorders such as irritable bowel syndrome, ulcers, excess pancreatic or gastric secretion, acute pancreatis, motility disorders, central nervous system disorders caused by CCK s interaction with dopamine such as neuroleptic disorders, tardive, dyskinesia, Parkinson s disease, psychosis or Gilles de la Tourette Syndrome, and disorders of appetite regulatory systems. CCX In Vitro Activity of Formula 1 Compounds The CCX biological activity of the compounds of Formula 1 have been evaluated using an 125I CCK receptor binding assay and in vitro isolated tissue preparations.Materials and Methods 1. CCX receptor binding pancreas 125 CCK 33 was radiolabeled with 1 Bolton Hunter reagent 2000 Ci mmole as described bySankara et al. J. Biol. Chem. 254 9349 9351, 1979 1. Receptor binding was performed according to Innis and Snyder Proc. Natl. Acad. Sci. 77 6917 6921, 1980 with the minor modification of adding the additional protease inhibitors, phenylmethane sulfonyl fluoride and o phenanthroine. The latter two compounds have no effect on the 125I CCK receptor binding assay. Male Sprague Dawley rats 200 350g were sacrificed by decapitation. The whole pancreas was dissected free of fat tissue and was homogenized in 20 volumes of ice cold 50 mM, Tris HC1 pH 7.7 at 250C with a Brinkman Polytron PT 10. The homogenates were centrifuged at 48,000 g for 10 min.Pellets were resuspended in Tris Buffer, centrifuged as above and resuspended in 200 volumes of binding assay buffer 50 mM Tris HC1, pH 7.7 at 250, 5 mM dithiothriethel, 0.1 mM bacitracin, 1.2 mM phenylmethane sulfonyl fluoride and 0.5 mM o phenanthroline . For the binding assay, 25 p1 of buffer for total binding or unlabeled CCK 8 sulfate to give a final concentration of 1pM for nonspecific binding or the compounds of Formula 1 for determination inhibition of 1251 CCX binding and 25 p1 of 5I CCK 33 30,000 40,000 cpm were added to 450 p1 of the membrane suspensions in microfuge tubes. All assays were run in duplicate or triplicate.The reaction mixtures were incubated at 370C for 30 minutes and centrifuged in a BeckmanMicrofuge 4 minutes immediately after adding 1 ml of ice cold incubation buffer. The supernatant was aspirated and discarded, pellets were counted with aBeckman gamma 5000. CCX Receptor Binding Brain CCK 33 was radiolabeled with and the binding was performed according to the description for the pancreas method with modifications according toSaito, et al. J. Neurochem, 37, 483 490 1981 . Hall Hartley guinea pigs 300 500 g were sacrificed by decapitation and the brains were removed and placed in ice cold 50 mM, Tris HC1 plus 7.58 g l Tritma 7.4 pH 7.4 at 250C Cerebral cortex was dissected and used as a receptor source. Each gram of fresh guinea pig brain tissue was homogenized in 10 ml of Tris Trizma buffer with a Brinkman polytron PT 10. The homogenates were centrifuged at 42,000 g for 15 minutes. Pellets were resuspended inTris Buffer, centrifuged as above and resuspended in 200 volumes of binding assay buffer 10 mM HEPES, pH 7.7 at 250C, 5 mM Mg Cl2, mM EGTA, 0.4 BSA bovine serum albumin and 0.25 mg ml bacitracin . For the binding assay, 25 ill of buffer for total binding or unlabeled CCK 8 sulfate to give a final concentration of 1pM for nonspecific binding or the compounds ofFormula 1 for determination inhibition of 125I CCK binding and 25 ul of 125I CCK 33 30,00 40,000 cpm were added to 450 p1 of the membrane suspensions in microfuge tubes. All assays were run in duplicate or triplicate. The reaction mixtures were incubated at 250C for 2 hours and centrifuged in a BeckmanMicrofuge 4 minutes immedidately after adding 1 ml of ice cold incubation buffer. The supernatant was aspirated and discarded, pellets were counted with aBeckman gamma 5000. In Vitro Results 1. Effect of The Compounds of Formula 1 on 125I CCK 33 receptor binding Compounds of Formula 1 inhibited specific 125I CCX 33 binding in a concentration dependent manner with an IC50 less than or equal to 100 M such as, for example l t butoxyearbonylmethyl 3 D N acetyltryptophanyl aminohomodihydrocarbostyril, IC50 1.6 uM l t butoxycarbonylmethyl 3 L N acetyltryptophanyl aminohomodihydrocarbostyril, IC50 2.8 gM 1 t butoxycarbonylmethyl 3 L carbonylbenzyloxy tryptophanyl aminohomodihydrocarbostyril, IC50 1.2 M 1 methyl 3 1 carboethoxy 3 phenyl 1 propyl amino homodihydrocarbostyril, IC50 60 gM and, l carbomethoxymethyl 3 3 indole methyl aminohomo dihydrocarbostyril, IC50 15 WM. Thus, in accordance with the present invention, there is provided a pharmaceutical composition for and a method of treating gastrointestinal disorders, central nervous system disorders, or regulating appetite which comprises administering to a patient in need of such treatment a pharmaceutically effective amount of a compound ofFormula 1. For administration, the compositions of the invention can also contain other conventional pharmaceutically acceptable compounding ingredients, as necessary or desired. ch ingredients are generally referred to as carriers or diluents.Conventional procedures for preparing such compositions in appropriate dosage forms can be utilized. Whatever the dosage form, it will contain a pharmaceutically effective amount of the compounds of the invention. The present compositions can be administered orally or other than orally e.g., parenterally, by insufflation, topically, rectally, etc. using appropriate dosage forms e.g., tablets, capsules, suspensions, solutions, and the like, for oral administration suspension emulsions, and the like, for parenteral administration solutions for intravenous administration and ointments, transdermal patches, and the like, for topical administration. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparation.Tablets containing the active ingredient in admixture with non toxic pharmaceutically acceptable excipients may also be manufactured by known methods. The excipients used may be for example, 1 inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate 2 granulating and disintegrating agents such as corn starch, or alginic acid 3 binding agents such as starch, gelatin or acacia, and 4 lubricating agents such as magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.They may also be coated by the techniques described in U.S. Patents 4,256,108 4,160,452 and 4,265,874 to form osmotic therapeutic tablets for controlled release. In some cases, formulations for oral use may be in the form of hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil. Aqueous suspensions normally contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.Such excipients may be 1 suspending agents such as sodium carboxymethylcellulose, methyl cellulose, hydroxypropylmethyl cellulose, sodium alginate, polyvinyl pyrrolidone, gum tragacanth and gum acacia 2 dispersing or wetting agents which may be a a naturally occurring phosphatide such as lecithin, b a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate, c a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadeca ethyleneoxycetanol, d a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol such as polyoxyethylene sorbitol monooleate, or e a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride, for example polyoxy ethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example, ethyl or n propyl p hydroxybenzoate one or more coloring agents one or more flavoring agents and one or more sweetening agents such as sucrose or saccharin. Oily suspension may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid. Dispersible powders and gnules are suitable for the preparation of an aqueous suspension. They provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, those sweetening, flavoring and coloring agents described above may also be present. The pharmaceutical compositions of the invention may also be in the form of oil in water emulsions. The oily phase may be a vegetable oil such as olive oil or arachis oils, or a mineral oil such as liquid paraffin or a mixture thereof.Suitable emulsifying agents may be 1 naturallyoccurring gums such as gum acacia and gum tragacanth, 2 naturally occurring phosphatides such as soy bean and lecithin, 3 esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan monooleate, 4 condensation products of said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents. Syrups and elixirs may be formulated with sweetening agents, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to known methods using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3 butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer s solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. A composition of the invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols. For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compositions of the invention are employed. Treatment dosage for human beings can be varied as necessary. Generally, daily dosages of the compounds of the invention can range from about 0.5 mg to about 1,000 mg preferably, from about 5 mgs to about 500 mg. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.For example, a formulation intended for oral administration may contain, for example, from 5 mg to 500 mg of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy. The compounds of this invention can also be administered in combination with antihypertensives and or diuretics and or calcium entry blockers. The compounds of Formula 1 can be prepared by the methods shown in the following Reaction Scheme wherein R R6, y and p are as defined above unless otherwise indicated. As will be evident to those skilled in the art and as demonstrated in the Examples hereinafter, reactive groups not involved in the reactions, such as amino, carboxy, mercapto, etc., may be protected by methods standard in peptide chemistry prior to the coupling reactions and subsequently deprotected to obtain the desired products. REACTION SCHEME Process AEMI19.1 EMI20.1 EMI21.1 Process BEMI21.2 Process A Benzofused lactam 2 ring size ranging from 6 to 8, prepared from a precursor ketone by a procedure of Blicke et al., J. Am. Chem. Soc., 76, 2317 1954 , is converted to 3 , with PX5 where X Br or C1 Nagasawa et al., J. Med. Chem., 14, 501 1971 .Reaction of 3 with sodium or lithium azide in a suitable solvent such as DMF or ethanol see, for example, Brenner et al., Helv. Chem. Acta, 41, 181 1958 affords 4 which can be alkylated with an alkylhalide or iodoester in the presence of a strong base, like sodium hydride, in a solvent such as DMF or THF to produce 5 . Reduction of 5 with hydrogen and a suitable catalyst, such as palladium on carbon, affords 6 . Alternatively, 3 may be alkylated in the presence of a strong base, like sodium hydride, and the intermediate 6 converted to 7 by reaction with an azide salt as described above. Intermediate 7 may be reductively coupled with an aldehyde, ketone, keto acid or ketoester in a solvent such as ethanol using a catalyst such as palladium on carbon to afford la X absent . la may also be prepared using sodium cyanoborohydride to effect reduction. Alternatively, intermediate 7 may be coupled with a carboxylic acid using a coupling agent such as dicyclohexylcarbodiimide DCC and an activator such as l hydroxybenzotriazole HOBt in an aprotic solvent such as chloroform or THF to affordEMI22.1 Compound lb can also be prepared by reacting 7 with an acid chloride and a tertiary amine such as triethylamine in an aprotic solvent such as chloroform or THF. The acid chloride is prepared from a carboxylic acid and thionyl chloride or PC13 in an aprotic solvent such as chloroform.Process B Compound la Y CO2H may be further elaborated as follows. The acid la can be reacted with an alkoxychloroformate such as ethylchloroformate , a tertiary amine such as triethylamine in an aprotic solvent such as tetrahydrofuran THF to give, upon filtration, a mixed anhydride intermediate which is then reacted with an excess of diazomethane in ether to give diazomethylketone 8 . Reaction of 8 with trifluoroacetic acid TFA . Followed by stirring in methanol or ethanol gives hydroxymethyl ketone lc.EMI23.1 In the above preparations, the keto acid or ester can be represented by the formulaEMI23.2 and may be, for example, 2 oxo 4 phenyl butyric acid. Other a keto acids or esters may be utilized to prepare other compounds of the present invention for various definitions of R and R1. Such a keto acids are readily available or may be prepared by well known techniques. For example, synthons such as EMI24.1 can be converted to a keto acids or esters using methods involving alkylation followed by hydrolysis as described in the literature. An excellent method involves the reaction of Grignard reagents R1MgX with ClCOCO2Y or YO2CCO2Y. Another method involves condensing substituted acetic acid esters with diethyl oxalate followed by hydrolytic decarboxylation under acidic conditions to obtain a keto acids. Carefully controlled acid hydrolysis in alcohol of acyl cyanides, which are prepared from acid chlorides and cuprous cyanide, also proves to be a viable synthetic route to a keto esters.Nucleophilic displacement reactions on chloro or bromo pyruvic acid ester can also be used to produce a variety of interesting a keto acids esters . In these formulae, Y is a group such as loweralkyl or benzyl and protecting groups are employed as necessary in the R1 group if an interfering functionality is present. Additional compounds of Formula 1 can be prepared by employing the keto acids and esters listed in Table I below. TABLE I R C OKeto Acids and Esters of the Formula COORÃšEMI25.1 EMI26.1 EMI27.1 precursor for the corresponding amino compound EMI27.2 precursor for the corresponding amino compound EMI27.3 p CH3S CH2CH2COCOOH q CH3 2 CH2CH2COCOOH r CBz HN CH2 3 COCOOH precursor for the corresponding amino compound EMI28.1 The following examples set forth the best mode currently known for preparing the compounds of the invention and are not intended to be construed as limitative, but illustrative, thereof. Unless otherwise indicated, all temperatures are in degreesCelcius. EXAMPLE 1A. 3 Bromo homodihydrocarbostyrilEMI29.1 To a solution of 15 gm 0.093 mol of homo dihydrocarbostyril L. H. Briggs, J.C.S., 456 1937 in 200 ml of chloroform was added in increments over a period of an hour 19 gm of PC15 at which time was added 140 mg of iodine followed by a slow dropwise addition of 90 ml of a 1M solution of bromine in chloroform. The reaction mixture was warmed to room temperature where stirring was continued a further 1 hour. The crude reaction mixture was concentrated in vacuo and then partitioned between water, ice and chloroform. The aqueous layer was extracted 2 times with methylene chloride and the combined organic fractions were filtered through MgSO4 and concentrated in vacuo. The crude bromide D was chromatographed silica, 2 1 ether hexanes to give 6.5 gm of pure D bromide. TLC silica, 2 1 ether hexanes Rf 0.65 NMR CDC13, TMS 2.4 3.0 m, 4H 4.4 4.7 t, lH 7.2 s, 4H 9.2 bs, 1H IR 1650 cm 1 mass spectrum M 239, m e 241 M , 2 160 M 2 Br 132 C O B. 3 Azido homodihydrocarbostyrilEMI30.1 To a solution of 9.98 gm 0.0417 mol of 3 bromo homodihydrocarbostyrilin 200 ml of DMF was added 10.8 gm of sodium azide stirring 12 hours at 600C at which time the DMF was removed at reduced pressure. To the crude reaction mixture was added 50 ml of water and the mixture was then extracted 3 times with 50 ml of chloroform.The combined organic fractions were combined, washed with 25 ml of a saturated solution of NaCl, filtered through MgSO4 and concentrated at reduced pressure. Chromatography silica, 2 1 ether hexanes gave 7.92 gm of pure E azide. m.p. 150 1510CTLC silica, 2 1 ether hexanes Rf 0.71El. An. Calc. for CloHloN4O N, 27.71 C, 59.39 H, 4.98Found N, 27.27 C, 59.25 H, 4.98 NMR CDC13, TMS 2.2 2.8 m, 4H , 3.6 4.0 dd, lH 7.2 bs, 4H 9.2 bs, 1HEIR N3 2130,CO 1678 mass spectrum M 202, m e 174 M N2 146 C O C. 3 Azido l methylhomodihydrocarbostyrilEMI31.1 To a suspension of 151 mg of sodium hydride 50 dispersion in oil washed 3 times with hexanes in 3 ml of THF at OOC was added dropwise a solution of 0.6 gm of 3 azidohomodihydrocarbostyril and 0.37 ml of methyl iodide in 3 ml of THF. The reaction was carefully monitored by tlc silica, 7 3 hexane ethyl acetate until reaction was complete at which time it was quenched with 10 ml of saturated NH4Cl, diluted with 10 ml of H2O and extracted 2 times with 10 ml of ethyl acetate. The combined organic layers were filtered through MgSO4, concentrated in vacuo and chromatographed silica, 7 3, hexane ethyl acetate to give 0.45 gm of product.NMR CDC13, TMS 2.0 3.1 m, 4H 3.4 S, 3H 3.5 3.8 overlapping d, lH 7.2 S, 4H . D. 3 Amino l methylhomodihydrocarbostyrilEMI32.1 A solution of 2.7 gm of 3 azido l methyl homodihydrocarbostyril in 18 ml of absolute ethanol with 0.27 gm of pd C 10 was hydrogenated for 12 hours at room temperature and 40 lbs of H2. The reaction was subsequently filtered and the ethanol removed at reduced pressure to give 2.6 gm of amine.NMR CD30D, TMS 1.8 3.0 m, 4H 3.4 S, 3H 3.4 3.8 M, lH 7.2 M, 4H .E. l Methyl 3 l Carboethoxy 3 phenyl l propyl aminohomodihydrocarbostyr il EMI32.2 A solution of 2.6 gm of l methyl 3 amino homodihydrocarbostyril 8.65 gm of ethyl 4 phenyl2 oxobutyrate and 0.72 gm of acetic acid in 15 ml of absolute ethanol was stirred 1 hour at room temperature. To the stirred solution was added dropwise over a 16 hour period a solution of 1.9 gm ofNaCNBH3 in 12 ml of ethanol. After stirring a further 8 hours, the reaction was concentrated and partitioned between H2O and ethylacetate. After extracting twice with ethyl acetate the combined organic layers were filtered through MgSO4, concentrated in vacuo and chromatographed silica, 7 3, hexane ethylacetate to give two diasteriomeric racemates.Racemate A 440 mgTLC silica, 7 3, hexane ethylacetate Rf 0.21NMR CDC13, TMS 1.2 t, 3H 1.6 3.2 m, llH 3.4 s, 3H 4.15 q, 2H 7.1 7.3 overlapping singlets 9H .El. An. Calc. for C23H28O3N2 1 4 H2O N, 7.28 C, 71.75 H, 7.33Found N, 7.22 C, 72.06 H, 7.44Racemate B 520 mg TLC silica, 7 3, hexane ethylacetate Rf 0.15NMR CDC13, TMS 1.1 t, 3H 1.6 3.5 m, llH 3.3 S, 3H 4.0 q, 2H 7.15 S, 9H .El. An. Calc. for C23 28 3N2 1 2 H2O N, 7.19 C, 70.93 H, 7.25Found N, 7.15 C, 71.33 H, 7.35 EXAMPLE 2A. l t Butoxycarbonylmethyl 3 azido homodihydro carbostyrilEMI33.1 To a suspension of 1 gm of sodium hydride 50 dispersion in oil washed 3 times with hexanes in 20 ml of ThF at OOC was added dropwise a solution of 4.2 gm 0.02 mol of 3 azido homodihydrocarbostyril Compound B, Example 1 and 3 ml of t butyliodo acetate in 20 ml of THF. The reaction was carefully monitored by TLC silica, 2 1 ether hexanes until reaction was complete at which time the reaction was quenched with 30 ml of saturated NH4C1, diluted with 20 ml H2O and extracted 3 times with 50 mlCH2C12. The combined organic layers were filtered, concentrated in vacuo and chromatographed silica, 2 1 ether hexanes to give 4.5 gm of pure product F.m.p. 103 1040CTLC silica, 2 1 ether hexanes Rf 0.74 El. An. Calc. for C16H20N403 N, 17.71 C, 60.74 H, 6.37Found N, 17.39 C, 60.54 H, 6.61NMR CDC13, TMS 1.5 s, 9H , 2.2 3.4 m, 4H 3.5 4.0 overlapping doublets, lH 4.2 4.8 ABq, 2H 7.2 s, 4H mass spectrum M 316, m e 288 M N2 260 M C4H9 B. l t Butoxycarbonylmethyl 3 aminohomodihydro carbostyr il EMI34.1 A solution of 8.01 gm of l t butoxycarbonylmethyl 3 azidohomodihydrocarbostyril in 150 ml of absolute ethanol with 0.8 gm of Pd C 10 was hydrogenated for 12 hr at room temperature and 40 lbs of H2. The reaction was subsequently filtered and the ethanol removed at reduced pressure to give 7.05 gm of pure amine G.m.p. 107 1090C. El. An. Calc. for C16H22N2O3.1 2H2O N, 9.36 C, 64.19 H, 7.41Found N, 9.18 C, 64.17 H, 7.53NMR D2O, CDC13, TMS 1.4 s, 9H , 2.2 3.8 m, 5H 4.1 4.7 ABq, 2H 7.05 bs, 4H IR C O 1735, 1660 mass spectrum M 290, m e 262 M C O 234 M C4H8 217 M C4HgO C. l Carbomethoxymethyl 3 aminohomodihydro carbostyrilEMI35.1 A solution of 1 gm of l t butoxycarbonylmethyl 3 aminohomodihydrocarbostyril in 20 ml of methanol was saturated with HC1, the flask was sealed and the reaction allowed to stir 5 hours at room temperature. The reaction mixture was concentrated in vacuo and partitioned between dilute NaHCO3 and ethylacetate.The H2O layer was extracted 2 times with ethylacetate and the combined organic layers were filtered through MgSO4 and concentrated at reduced pressure to give 850 mg of product.NMR CDC13, TMS 1.8 3.6 m, 7H 3.65 S, 2H , 4.5 ABq, 2H 7.1 S, 4H .D. l Carbomethoxymethyl 3 3 indole methyl amino homodihydrocarboxtyrilEMI36.1 A solution of 0.5 gm of l carbomethoxymethyl 3 aminohomodihydrocarbostyril, 0.87 gm ofIndole 3 carboxaldehyde and 0.12 ml of acetic acid in 6 ml of methanol was stirred 1 hour at room temperature. To the stirred solution was added dropwise over 6 hours a solution of 0.32 gm ofNaCNBH3 in 6 ml of methanol. After stirring an additional 8 hours, the reaction was concentrated in vacuo, and partitioned between H2O and ethylacetate. The organic layer was filtered throughMgSO4, concenKrated and chromatographed silica, 9 1 1, ethylacetate acetonitrile methanol to give 0.16 gm of said product.TLC silica, 9 1 1, ethylacetate acetonitrile methanol Rf 0.36. NMR CDC13, TMS 1.8 3.6 m, 6H 3.7 s, 3H 3.8 ABq, 2H 4.6 s, 2H 6.9 m, lH 7.1 bs, 7H 7.5 7 7 m, lH 8.4 bs, 1H . EXAMPLE 3A. l Carbomethoxymethyl 3 aminohomodihydrocarbostyrilEMI37.1 A solution of 1 gm of l t butoxycarbonylmethyl 3 aminohomodihydrocarbostyril Compound B,Example 2 in 20 ml of methanol was saturated withHC1, the flask sealed and the reaction allowed to stir 6 hours at room temperature. The reaction mixture was concentrated in vacuo and partitioned between dilute NaHCO3 and ethylacetate. The H2O layer was extracted 2 times with ethylacetate and the combined organic layers were filtered through MgSO4 and concentrated at reduced pressure to give 850 mg of product.NMR CDC13, TMS 1.8 3.6 m, 7H 3.65 s, 2H , 4.5 ABq, 2H 7.1 s, 4H .B. l Carbomethoxymethyl 3 1 t butoxycarbonyl 3 phenyl l propyl aminohomodihydrocarbostyril Racemate mixture EMI38.1 A solution of 4.3 gm of l carbomethoxymethyl3 aminohomodihydrocarbostyril, 8 gm of t butyl 4 phenyl 2 oxobutyrate and 1 gm of acetic acid in 35 ml of ethanol was stirred 1 hour at room temperature. To the stirred solution was added dropwise over a 10 hour period a solution of 2.67 gm of NaCNBH3 in 35 ml of ethanol. After stirring for an additional 9 hours, the reaction was concentrated in vacuo and partitioned between H2O and ethylacetate.After extracting twice with ethylacetate the combined organic layers were filtered through MgSO4, concentrated and chromatographed silica, 1 1 ethylacetate hexanes to give two diasteriomeric racemates of which racemate B was retained.Racemate B 3 gm TLC silica, 1 1 ethylacetate hexanes Rf 0.64NMR CDC13, TMS 1.2 s, 9H 1.5 3.2 m, llH 3.5 s, 3H 3.4 ABq, 2H 7.0 s, 9H El. Ann Calc. for C27H34N205 N, 6.00 C, 69.50 H, 7.35Found N, 5.84 C, 69.52 H, 7.27. C. 1 Carbomethoxymethyl 3 1 carboxy 3 phenyl 1 propyl aminohomodihydrocarbostyrilEMI39.1 A solution of 2.5 gm of l carbomethoxymethyl 3 1 t butoxyearbonyl 3 phenyl 1 propyl aminohomodi hydrocarbostyril, racemate B, in 20 ml of trifluoroacetic acid was stirred 12 hours at room temperature where upon it was concentrated in vacuo to yield 1.69 gm of the title compound.NMR CD3OD, tms 2.0 3.2 m, 8H 3.6 s, 3H 3.6 4.1 m, 2H 3.6 s, 2H 7.1 7.4 overlapping s, 9H .D. 1 Carbomethoxymethyl 3 1 azidomethylcarbonyl 3 phenyl 1 propyl aminohomodihydrocarostyrilEMI39.2 To a solution of 1.54 gm of l carbomethoxy methyl 3 1 carboxy 3 phenyl 1 propyl aminohomodihydroc arbostyril in 15 ml of THF at OOC was added with stirring 0.56 ml of triethylamine followed by 0.32 ml of methylchloroformate. Stirring at 0 C was continued for 15 minutes whereupon the reaction mixture was filtered in a nitrogen atmosphere to remove precipitated triethylaminehydrochloride. To the filtrate at 0 C was added a solution of diazomethane in ether. The reaction s progress was monitored by tlc silica, 1 1 hexane ethylacetate and diazomethane solution was added as needed. When the reaction was complete 10 hours , the solution was filtered and solvents removed at reduced pressure. The crude product was purified by chromatography silica, 1 1, hexane ethylacetate to give 1.25 gm of diazoketone.TLC silica, 1 1, hexane ethylacetate Rf 0.50NMR CDC13, TMS 1.7 3.1 m, 8H 3.6 s, 3H 3.9 4.1 m, 2H 4.5 ABq, 2H 5.5 s, lH 7.1 7.3 overlapping singlets, 9H .E. 1 Carbomethoxymethyl 3 l 2 hydroxy l oxoethyl 3 phenyl 1 propyllaminohomodihydrocarbostyril EMI40.1 A solution of 0.3 gm of l carbomethoxymethyl 3 1 azidomethylcarbonyl 3 phenyl 1 propyl aminohomo dihydrocarbostyril in 5 ml of trifluoroacetic acid was stirred at room temperature for 3 hours at which time the acid was removed at reduced pressure. The crude reaction mixture was dissolved in 5 ml of methanol an the solution stirred 6 hours at room temperature, where upon the methanol was removed in vacuo. The crude product was purified by chromatography silica, 1 1, ethylacetate hexane to give the title compound.TLC silica, 1 1, ethylacetate hexane Rf 0.44NMR CDC14, TMS 1.7 3.2 m, l1H 3.6 s, 3H 4.0 5.0 m, 5H 7.2 bs, 9H .mass spectrum M 424, m e 423 M 1 , 365 M CO2CH3 . EXAMPLE 4 l t Butoxycarbonylmethyl 3 D N acetyltryptophanyl aminohomodihydrocarbostyrilEMI41.1 To a solution of 0.3 gm of l t butoxy carbonylmethyl 3 aminohomodihydrocarbostyril Compound B, Example 2 and 0.25 gm of N acetyl Dtryptophan in 5 ml of chloroform at room temperature was successively added 0.15 gm of l hydroxybenzo triazole and 0.24 gm of dicyclohexylcarbodiimide.After stirring for 12 hours at room temperature the reaction mixture was filtered and the filtrate was washed with H2O, filtered through MgSO4 and concentrated in vacuo. The product was chromatographed to give two diasteriomeric raceinates. Racemate A 150 mg TLC silica, 9 1 ethylacetate acetonitrile Rf 0.416NMR CDC13, TMS 1.4 s, 9H 1.9 s, 3H 2.3 3.3 m, 6H 3.9 4.7 m, 2H 4.3 ABq, 2H 6.4 6.6 overlapping d, 2H 6.9 7.5 m, 9H 8.6 bs, 1H . Racemate B 200 mg TLC silica, 9 1, ethylacetate acetonitrile Rf 0.416NMR CDC13, TMS 1.35 s, 9H , 1.8 s, 3H 2.1 3.3 m, 6H 4.3 ABq, 2H 4.0 4.8 m, 2H 6.3 6.7 overlapping d, 2H 6.8 7.5 m, 9H 8.5 bs, 1H . EXAMPLE 5 l t Butoxycarbonylmethyl 3 L N acetyltryptophanyl aminohomodihydrocarbostyrilEMI42.1 To a solution of 0.3 gm of l t butoxycarbonylmethyl 3 aminohomodihydrocarbostyril Compound B, Example 2 and 0.25 gm ofN acetyl D tryptophan in 5 ml of chloroform at room temperature was successively added 0.15 gm of l hydroxybenzotriazole and 0.24 gm of dicyclohexylcarbodiimide. After stirring for 12 hours the reaction mixture was filtered. The filtrate was washed with H2O, filtered through MgSO4 and concentrated in vacuo and chromatographed to give two diasteriomeric raceinates. Racemate ATLC silica, 9 1 ethylacetate acetonitrile Rf 0.26NMR CDC13, TMS 1.4 s, 9H 1.8 s, 3H 2.3 3.3 m, 6H 3.9 3.7 m, 2H 4.3 ABq, 2H 6.4 6.7 overlapping d, 2H 6.8 7.4 m, 9H 8.6 bs, 1H . Racemate BTLC silica, 9 1, ethylacetate acetonitrile Rf 0.26NMR CDC13, TMS 1.3 s, 9H , 1.7 s, 3H 2.1 3.2 m, 6H 4.3 ABq, 2H 4.1 4.8 m, 2H 6.6 7.7 m, llH . EXAMPLE 6 l t Butoxyearbonylmethyl 3 L N carbobenzyloxytrypto phanyl aminohomodihydrocarbostyrilEMI44.1 To a solution of 0.3 gm of l t butoxycarbonylmethyl 3 aminohomodihydrocarbostyril Compound B, Example 2 and 0.36 gm ofN carbobenzyloxy L tryptophan in 5 ml of chloroform at room temperature was successively added 0.15 gm of l hydroxybenzotriazole and 0.24 gm of dicyclo hexylcarbodiimide. After stirring for 4 hours the reaction mixture was filtered, concentrated in vacuo and chromatographed to give two diasteriomeric racemates.Racemate A 100 mg TLC silica, 1 1 ethylacetate hexane Rf 0.27NMR CDC13, TMS 1.65 s, 9H 1.8 3.4 m, 6H 4.35 ABq, 2H 4.1 4.6 m, 2H 5.1 s, 2H 5.5 d, 1H 6.6 d, 1H 6.8 7.6 m, 14H 8.3 s, 1H . Racemate B 130 mg TLC silica, 1 1, ethylacetate hexane Rf 0.27NMR CDC13, TMS 1.4 s, 9H , 1.7 3.3 m, 6H 4.35 ABq, 2H 4.2 4.6 m, 2H 5.0 s, 2H 5.4 d, lH 6.7 d, 1H 6.8 7.4 m, 14H 8.4 bs, 1H . EXAMPLE 7 l t Butoxycarbonylmethyl 3 D N carbobenzyloxytryptophanyl aminohomodihydrocarbostyrilEMI45.1 To a solution of 0.3 gm of l t butoxycarbonylmethyl 3 aminohomodihydrocarbostyril Compound B, Example 2 and 0.36 gm ofN carbobenzyloxy D tryptophan in 5 ml of chloroform at room temperature was successively added 0.15 gm of l hydroxybenzotriazole and 0.24 gm of dicyclo hexylcarbodiimide. After stirring 12 hours at room temperature, the reaction mixture was filtered and partitioned between H2O and chloroform. The chloroform fraction was filtered through MgSO4, concentrated in vacuo and chromatographed to give two diasteriomeric racemates. Racemate A 150 mg TLC silica, 1 1 ethylacetate hexane Rf 0.27NMR CDC13, TMS 1.4 s, 9H 1.8 3.4 m, 6H 4.35 ABq, 2H 4.1 4.6 m, 2H 5.1 s, 2H 5.55 d, lH 6.6 d, lH 6.8 7.4 m, 14H 8.4 bs, 1H . Racemate B 200 mg TLC silica, 1 1, ethylacetate hexane Rf 0.27NMR CDC13, TMS 1.4 s, 9H , 2.0 3.4 m, 6H 4.4 ABq, 2H 4.2 4.6 m, 2H 5.1 s, 2H 5.55 d, lH 6.8 d, lH 6.8 7.5 m, 14H 7.6 bs, 1H . EXAMPLE 8 l Carbo t butoxymethyl 3 carbonyl 2 indolyl amino homod ihydrocarbostyr il EMI46.1 To a solution of indole 2 carboxylic acid 0.165 gm 0.001 mol in 3 ml of chloroform at room temperature there was added 0.25 ml of thionyl chloride. This solution was stirred 8 hours at room temperature whereupon it was evaporated in vacuo. To a solution of the resulting acid chloride in 3 ml of chloroform there was added l t butoxycarbonylmethyl 3aminohomodihydrocarbostyril 0.3 gm, 0.001 mol and 0.14 ml of triethylamine at room temperature. The reaction was monitored by tlc silica, 1 1,EtOAc hexanes . After 3 hours, the starting material had been converted to a nonpolar product. The reaction mixture was then partitioned between ethylacetate and water.After extracting the water layer with ethylacetate, the combined organic layers were dried over Na2SO4, filtered through MgSO4, evaporated at reduced pressure and chromatographed, silica, 2 1, hexanes ethylacetate to give 0.3 gm of product.TLC silica, 1 2, ethylacetate hexanes Rf 0.77 NMR CDC13, TMS 1.5 s, 9H0, 1.9 3.5 m, 5H , 4.5 ABq, m, 3H , 6.8 7.6 m, 9H .mass spectrum M 433, m e 377 M C4H8 , 360 C H 0 EXAMPLE 9 l Carboxymethyl 3 carbonyl 2 indolyl aminohomodihydrocarbostyrilEMI47.1 To a solution of 1 carbo t butoxymethyl 3 carbonyl 2 indolyl aminohomodihydrocarbostyril 0.2 gm in 2 ml of chloroform at room temperature was added 2 ml of trifluoroacetic acid. The reaction was stirred 3 hours whereupon it was evaporated in vacuo to give 0.13 gm of product.mass spectrum M 377 EXAMPLE 10 l Carbo t butoxymethyl 3 1 p chlorobenzoyl amino homodihydrocarbostyr il EMI48.1 To a solution of l t butoxycarbonylmethyl3 aminohomodihydrocarbostyril 0.5 gm, 0.0017 mol in 12 ml of methylene chloride there was added 0.297 gm of 4 chlorobenzoic acid followed by 0.25 gm of 1hydroxybenzotriazole and 0.39 gm of dicyclohexylcarbodiimide. The reaction mixture was stirred 12 hours at room temperature whereupon it was filtered, washed with 5 Na2CO3, 5 citric acid, and saturatedNaHCO3. The solution was then filtered throughMgSO4, evaporated in vacuo, and chromatographed silica, 7 3, hexanes ethylacetate to give 0.35 gm of product.TLC silica, 7 3, hexanes ethylacetate Rf 0.5El. An. Calc. for C23H25N2O4C1 N, 6.53 C, 64.41 H, 5.87.Found N, 6.07 C, 64.14 H, 5.86.NMR CDC13, TMS 1.5 s, 9H , 2.0 3.5 m.4H , 4.4 ABq, 2H , 4.4 4.9 m, 1H , 7.1 7.8 m, 8H mass spectrum M 429 EXAMPLE 11 1 Carboxymethyl 3 1 p chlorobenzoyl aminohomodihydrocarbostyrilEMI49.1 A solution of l carbo t butoxymethyl 3 l p chlorobenzoyl aminohomodihydrocarbostyril in 5 ml of trifluoroacetic acid was stirred for 12 hours at room temperature whereupon it was evaporated in vacuo to give 0.17 gm of the title compound.NMR CDC13, CD30D, TMS 2.0 3.6 m, 4H , 4.5 ABq, 2H , 4.6 4.9 m, 1H , 7.1 7.8 m, 8H .mass spectrum M 375 EXAMPLE 12 1 Carbo t butoxymethyl 3 benzoyl aminohomodihydrocarbostyrilEMI49.2 This compound 0.590 gm was prepared from 0.4 gm of l t butoxycarbonylmethyl 3 amino homodihydrocarbostyril Example 2, Compound B , 0.185 gm of benzoic acid, 0.205 gm of l hydroxybenotriazole and 0.313 gm of dicyclohexylcarbodiimide by a process analogous to Example 10.TLC silica, 7 3, hexanes ethylacetate Rf 0.3El. An. Calc. for C23H26N2O4.l 4 H2O N, 7.02 C, 69.24 H, 6.57Found N, 6.63 C, 69.68 H, 6.67NMR CDC13, TMS 1.5 s, 9H , 2.0 3.5 m, 4H , 4.4 ABq, 2H , 4.5 4.9 m, 1H , 7.1 8.2 m, 9H mass spectrum M 394 EXAMPLE 13 l Carbo t butoxymethyl 3 3,4 dichlorobenzoyl aminohomodihydrocarbosytrilEMI50.1 The titled compound 0.27 gm was prepared from 0.3 gm of l t butoxycarbonyl methyl 3 aminohomodihydrocarbostyril Example 2, Compound B , 0.217 gm of 3,4 dichlorobenzoic acid, 0.15 gm of l hydroxybenzotriazole and 0.23 gm of dicyclohexylcarbodiimide by a process analogous to Example 10.TLC silica, 7 3, hexanes ethylacetate Rf 0.49 NMR CDC13, TMS 1.5 s, 9H 1.7 3.5 m, 4H 4.4 ABq, 2H 4.5 4.9 m, lH 7.1 8.2 m, 7H mass spectrum M 462 EXAMPLE 14 l Carbo t butoxymethyl 3 4 nitrobenzoyl aminohomo dihydrocarbostyrilEMI51.1 The titled compound 0.29 gm was prepared from 0.3 gm of l t butoxycarbonylmethyl 3 aminodihydro carbostyril Example 2, Compound B , 0.19 gm of 4 nitrobenzoic acid, 0.15 gm of l hydroxybenzotriazole and 0.23 gm of dicyclohexylcarbodiimide by a procedure analgous to Example 10.TLC silica, 7 3, hexanes ethylacetate Rf 0.35NMR CDC13, TMS 1.5 s, 9H 1.8 3.4 m, 4H , 4.5 ABq, 2H 4.3 4.8 m, lH 7.2 8.3 m, 8H .mass spectrum M 410, m c 384 M CH2 EMI51.2 EXAMPLE 15 l t Butoxycarbonylmethyl 3 4 fluorobenzoyl aminohomodihydrocarbostyrilEMI52.1 The titled compound 0.38 gm was prepared from 0.3 gm of l t butoxycarbonylmethyl 3 aminohomodihydrocarbostyril Example 2, Compound B , 0.16 gm of 4 fluorobenzoic acid, 0.15 gm of l hydroxybenzotriazole and 0.23 gm of dicyclohexylcarbodiimide by a procedure analogous to Example 10.TLC silica, 7 3, hexanes ethylacetate Rf 0.43NMR CDC13,TMS 1.5 s, 9H 1.8 3.4 m, 4H 4.5 ABq, 2H 4.4 4.8 m, lH 6.7 8.2 m, 8H mass spectrum M 412 EXAMPLE 16 l t Butoxycarbonylmethyl 3 4 dimethylaminobenzoyl aminodihydrocarbostyrilEMI53.1 The titled compound 0.2 gm was prepared from 0.3 gm of l t butoxycarbonylmethyl 3 amino homodihydrocarbostyril Example 2, Compound B , 0.19 gm of 4 dimethylaminobenzoic acid, 0.15 gm of l hydroxybenzotriazole and 0.23 gm of dicyclohexyl carbodiimide by a procedure analogous to Example 10. TLC silica, 1 1, hexanes ethylacetate Rf 0.50NMR CDC13, TMS 1.4 s, 9H 1.8 3.4 m, 4H 2.8 s, 6H 4.4 ABq, 2H 4.4 4.8 m, lH 6.8 7.4 m, 8H mass spectrum M 437